EMN15/HOVON147: Adding carfilzomib to Rd significantly improves MRD negativity rates in patients with high-risk smoldering multiple myeloma

Multiple Myeloma (MM)

Deep and Sustained Responses with Quadruplet Carfilzomib (Kyprolis^®)-Based Regimens in Patients with NDMM

ASH 2024

Multiple Myeloma (MM)

AQUILA: Daratumumab significantly improves PFS in high-risk smoldering multiple myeloma

Multiple Myeloma (MM)

Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database

Blood Cancer J

Rajkumar SV, Mateos MV, Schaeffer M, Lin X, Bathija S, Gupta-Werner N, Lam A, Carson R, Dennis R, Kaila S, Matt K, Duran J, Lonial S

doi: 10.1038/s41408-024-01170-z

EHA 2025

Multiple Myeloma (MM)

GMMG-CONCEPT: Isatuximab plus KRd leads to high and sustained MRD negativity in transplant-eligible patients with high-risk NDMM

CHICAGO 2025

Head and Neck Cancer

LBA2: NIVOPOSTOP: Adding nivolumab to adjuvant cisplatin-radiotherapy improves DFS in high-risk patients with LA-SCCHN

SABCS 2024

Breast Cancer

OlympiA: Olaparib continues to demonstrate improved OS, IDFS and DDFS in patients with BRCA1/2-mutated HER2-negative high-risk early breast cancer

Multiple Myeloma (MM)

International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma

J Clin Oncol

Avet-Loiseau H, Davies FE, Samur MK, Corre J, D'Agostino M, Kaiser MF, Raab MS, Weinhold N, Gutierrez NC, Paiva SB, Neri P, Weisel K, Maura F, Walker BA, Bustoros M, Stewart AK, Usmani SZ, Hillengass J, Chng WJ, Keats JJ, Martinez-Lopez J, Sperling AS, Touzeau C, Zhan F, Raje NS, Cavo M, Bolli N, Ghobrial IM, Dhodapkar MV, Jagannath S, Spencer A, Parekh S, Bahlis NJ, Lonial S, Sonneveld P, Bergsagel L, Orlowski RZ, Morgan G, Mateos MV, Rajkumar SV, San Miguel JF, Anderson KC, Moreau P, Kumar S, Prósper F, Munshi NC

doi: 10.1200/JCO-24-01893

CHICAGO 2025

Breast Cancer

INAVO120: Inavolisib significantly improves OS when added to palbociclib and fulvestrant in patients with PIK3CA-mutated HR-positive, HER2-negative endocrine-resistant advanced breast cancer

Multiple Myeloma (MM)

The bone marrow NK cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy

Blood

Korst CLBM, Tahri S, Duetz C, Bruins WSC, de Jonge AV, de Jong MME, Fokkema C, Smits F, Groen K, Verkleij CPM, Frerichs KA, Papazian N, van Duin M, van Beek G, Hoogenboezem R, Baardemans T, Dal Collo G, Stoetman ECG, Cosovic M, Twickler I, Rentenaar R, Eken M, Homan-Weert PM, Saraci E, D'Agostino M, van der Velden VHJ, Sanders MA, Gay F, Broijl A, Moreau P, Sonneveld P, Zweegman S, Mutis T, Cupedo T, van de Donk NWCJ

doi: 10.1182/blood.2024026455

Related content

Deep and Sustained Responses with Quadruplet Carfilzomib (Kyprolis®)-Based Regimens in Patients with NDMM

AQUILA: Daratumumab significantly improves PFS in high-risk smoldering multiple myeloma

Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database

GMMG-CONCEPT: Isatuximab plus KRd leads to high and sustained MRD negativity in transplant-eligible patients with high-risk NDMM

LBA2: NIVOPOSTOP: Adding nivolumab to adjuvant cisplatin-radiotherapy improves DFS in high-risk patients with LA-SCCHN

OlympiA: Olaparib continues to demonstrate improved OS, IDFS and DDFS in patients with BRCA1/2-mutated HER2-negative high-risk early breast cancer

International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma

INAVO120: Inavolisib significantly improves OS when added to palbociclib and fulvestrant in patients with PIK3CA-mutated HR-positive, HER2-negative endocrine-resistant advanced breast cancer

The bone marrow NK cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy

Deep and Sustained Responses with Quadruplet Carfilzomib (Kyprolis^®)-Based Regimens in Patients with NDMM